Tricuspid Repair vs Replacement | Dr. Vishal Khullar

Tricuspid valve repair is preferred over replacement in most cases where the valve anatomy allows it. Repair preserves the native valve, avoids lifelong anticoagulation in most patients, and carries lower operative mortality than replacement in comparable populations. Replacement becomes necessary when the valve is too damaged to reconstruct, when organic disease has destroyed the leaflets, or when a prior repair has failed. The choice between them is determined by the underlying pathology, the degree of annular dilation, leaflet integrity, and the surgeon’s ability to achieve a durable repair intraoperatively.

According to Dr. Vishal Khullar, a Cardiac Surgeon in Mumbai, “Repair is almost always the first choice when the anatomy supports it. Replacement carries higher operative risk and commits the patient to either anticoagulation or a valve that will eventually wear out. We push for repair wherever it’s technically achievable.”

Two procedures. Different risk profiles and different long-term implications. Here is the clinical comparison that matters.

No anticoagulation burden: Mechanical replacement valves require lifelong warfarin. Repair avoids this entirely. Bioprosthetic valves reduce but don’t eliminate the anticoagulation question, and they deteriorate over time requiring eventual reoperation.

Operative mortality gap: Meta-analysis data from over 15,000 patients shows repair carries lower operative mortality than replacement, 8.4 percent versus 9.9 percent, with lower rates of renal failure and pacemaker implantation.

Durability trade-off: Repair is durable when technically well executed, but recurrent regurgitation occurs in a subset of patients. Replacement is more definitive in the short term but carries valve-specific complications over the long term.

Reoperation risk: If repair fails and reoperation is needed, the second operation carries higher mortality than a primary replacement. That risk factors into the initial decision, particularly in patients with multiple comorbidities.

For how tricuspid disease fits into the broader picture of right heart problems, read our blog on right heart failure.

Dr. Vishal Khullar is the Director of Cardiovascular and Thoracic Surgery, Heart and Lung Transplant at Fortis Hospital Mulund and Fortis S.L. Raheja Hospital, Mumbai. Over 30 years in the field. Training at Cleveland Clinic and Mayo Clinic in the USA. More than 7,000 completed procedures, including complex valve repair and replacement cases across all four valves.

His valve assessments are direct and anatomy-driven. Patients get a clear answer on whether repair is technically achievable for their specific case, and what the realistic long-term outcome looks like for each option. Call +91 99870 77880 to book your consultation.

1. NCBI StatPearls (NIH) – Tricuspid Valve Repair 
2. PMC (NIH) – Isolated Tricuspid Repair vs Replacement Meta-Analysis